Theramex gains €10M in licensing deal

Merck affiliate Laboratoire Theramex will pocket a €10 million licensing payment from Organon for the marketing rights to its new contraceptive EMM 310066, which has demonstrated efficacy in a Phase II trial. Theramex retains marketing rights in certain companies and also stands to garner milestones and royalties.

- read this story from AFX for more on the deal